Abstract
Neuroblastoma is the most common extracranial solid tumour in childhood. This enigmatic tumour shows extremely divergent behaviour, ranging from spontaneous regression, through maturation into differentiated cell types, to extreme chemoresistance, resulting in high mortality. The prognosis and treatment stratification of patients with this tumour is currently based on the International Neuroblastoma Risk Group (INRG) Staging System, which categorizes cases into high, intermediate, low and very low risk groups. In this classification system, tumour histology (Shimada) and biology (MYCN, segmental and numerical chromosomal aberrations including 1p, 11q) play a vital role, in addition to the age and extent of disease. Therefore, the key role of adequate solid tumour biopsy in the diagnosis and prognostic decision-making of patients with neuroblastoma cannot be overemphasised.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
